Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment

Nephron - Clinical Practice

Volumn 123, Issue 1-2, 2013, Pages 41-45

  Homma, Koichiro ^a,b   Homma, Yasuhiko ^a,c   Shiina, Yutaka ^c   Wakino, Shu ^b   Suzuki, Masaru ^b   Fujishima, Seitaro ^b   Hayashi, Koichi ^b   Hori, Shingo ^b   Itoh, Hiroshi ^b  

^a Hiratsuka Lifestyle related Disease and Homedialysis Clinic   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chronic kidney disease; Hemodialysis; Lipoprotein subfractions; Plasma lipoprotein

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VERY LOW DENSITY LIPOPROTEIN; HEPARIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FRACTIONATION; HEMODIALYSIS; HUMAN; LABORATORY TEST; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; ULTRACENTRIFUGATION; ADULT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; MAINTENANCE THERAPY; MOLECULAR WEIGHT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; JAPAN; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 84878724884     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000351506     Document Type: Article

References (36)

1. Appel G: Lipid abnormality in renal disease. Kidney Int 1991; 39: 169-183.
2. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M: Remnantlike particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997; 76: 7-14.
3. Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, Adachi M: Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis 2008; 197: 154-158.
4. Havel RJ, Kane JP: Introduction: structure and metabolism of plasma lipoproteins; in Scriver SP, Beaudet AL, Sly WS, Valle DV (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 2705-2716.
5. Crouse JR, Parks JS, Schey HM, Kahl FR: Studies of low-density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985; 26: 566-574.
6. Watson TD, Caslake MJ, Freeman BA, Griffin BA, Hinnie J, Packard CJ, Shepherd J: Determinants of concentrations in young normolipidemic subjects. Arterioscler Thromb 1994; 14: 902-910.
7. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB: Plasma apolipoprotein A-I absence associated with a marked reduction of high-density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982; 2: 16-26.
8. Nieminen MS, Mattila KJ, Aalto-Setala K, et al: Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 1992; 12: 58-69.
9. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC: Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281-2287.
10. Koniger M, Quaschning T, Wanner C, Schollmeyer P, Kramer-Guth A: Abnormality in lipoprotein metabolism in hemodialysis patients. Kidney Int Suppl 1999; 56:S248-S250.
11. Deighan CJ, Caslake MJ, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000; 35: 852-862.
12. McNamara JR, Jenner JL, Li Z, Wilson WF, Schaefer EJ: Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992; 12: 1284-1290 .
13. Griffin BA, Freeman DJ, Tait GW, Thompson J, Caslake MJ, Packard C, Shepherd J: Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-253.
14. Hirano T, Ito Y, Koba S, et al: Atherosclerosis and lipoproteins. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004; 24: 558-563.
15. Brunzell JD: Increased apo B in small dense LDL particles predicts premature coronary artery disease. Arterioscler Thromb Vasc Biol 2005; 25: 474-475.
16. Tall AR, Breslow JL, Rubin EM: Genetic disorders affecting plasma high-density lipoprotein; in Scriver SP, Beaudet AL, Sly WS, Valle DV (eds): The Metabolic and Molecular Bases of Inherited disease, ed 8. New York, Mc-Graw-Hill, 2001, pp 2915-2936.
17. Santamaria-Fojos, Hoeg JM, Assmann G, Breslow HB: Lecithin:cholesterol acyltransferase deficiency and fish eye disease; in Scriver SP, Beaudet AL, Sly WS, Valle DV (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 2817-2833.
18. Homma Y, Ozawa H, Kobayashi T, et al: A Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and highdensity lipoprotein, and on activities of lecithin:-cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994; 106: 191-201.
19. Noma A, Hata Y, Goto Y: Quantification of serum apolipoprotein A-I, A-II, B, C-II, C-III, and E by turbidimetric immunoassay: reference values, age-, sex-related differences. Clin Chim Acta 1993; 221: 147-157.
20. Nakajima K, Saito T, Tamura A, et al: Cholesterol in remnant-like lipoproteins in human serum using monoclonal antiapo B-100 and antiapo A-I immunoaffinity mixed gel. Clin Chim Acta 1993; 223: 53-71.
21. Manabe M, Abe T, Nozawa M, Maki A, Hirata M, Itakura H: New substrate for determination of serum lecithin:cholesterol acyltransferase. J Lipid Res 1987; 28: 1206-1215.
22. Nagano M, Yamashita S, Hirano K, et al: Point mutation (-69 G → A) in the promoter region of cholesterol ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. Arterioscler Thromb Vasc Biol 2001; 21: 985-990.
23. Havel RJ, Eder HA, Bragdon JL: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 1955; 34: 1346-1353.
24. Mahley RW, Rall SC: Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism; in Scriver SP, Beaudet AL, Sly WS, Valle DV (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 2835-2862.
25. Homma Y, Michishita I, Hayashi H, et al: Effects of low-dose simvastatin on the distribution of plasma cholesterol and oxidized lowdensity lipoprotein in three ultracentrifugally separated low-density lipoprotein subfractions: 12-month, open-label trial. J Atheroscler Thromb 2010; 17: 1049-1053.
26. Brunzell JD, Deeb SS: Familial lipoprotein lipase deficiency, apo CII deficiency, and hepatic lipase deficiency; in Scriver SP, Beaudet AL, Sly WS, Valle DV (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 2789-2815.
27. Mekki K, Prost J, Bouchenak M, Remaoun M, Belleville J: Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Atherosclerosis 2003; 169: 269-277.
28. Miida T, Miyazaki O, Hanyu O, et al: LCATdependent conversion of pre-β1-HDL into α-migrating HDL, is severely delayed in hemodialysis patients. J Am Soc Nephrol 2003; 14: 732-738.
29. Pahl MV, Ni Z, Sepassi L, Moradi H, Vazili ND: Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant 2009; 24: 2541-2546.
30. Reade V, Mezdour H, Reae R, Kandoussi M, Dracon M, Fruchart JC, Cachera C: Neutrallipid transfers and cholesteryl ester transfer protein in hemodialysis patients. Am J Nephrol 1996; 16: 394-401.
31. Kimura H, Miyazaki R, Suzuki S, Gejyo F, Yoshida H: Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis 2001; 38: 70-76.
32. Seiler S, Schlitt A, Jiang XC, et al: Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplantation 2008; 23: 3599-3604.
33. Packard CJ, Demant T, Stewart JP, et al: Apoprotein B metabolism and distribution of VLDL and LDL subfractions. J Lipid Res 2000; 41: 305-317.
34. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-1921.
35. Rosenson RS, Otovos JD, Freedman DS: Relation of lipoprotein subclass levels and lowdensity lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am J Cardiol 2002; 80: 89-94.
36. Homma K, Homma Y, Yamaguchi S, et al: Triglyceride-rich lipoproteins in chronic kidney disease patients undergoing maintenance hemodialysis. Int J Clin Pract 2012; 66: 394-398.